Abstract
Pituitary adenomas that hypersecrete functional follicle-stimulating hormone (FSH) and/or luteinizing hormone (LH) are extremely rare.
Although many nonfunctioning pituitary adenomas demonstrate positive immunoreactivity for FSH and LH, the overwhelming majority of these tumors are clinically silent, as discussed previously.
In women, functional gonadotroph adenomas may cause ovarian stimulation syndrome with enlarged ovaries, pelvic pain, galactorrhea, and/or menstrual abnormalities. Levels of circulating estradiol are typically elevated.
In men, excess levels of serum testosterone with testicular enlargement have been reported.
In boys, precocious puberty has been reported.
Functioning gonadotroph adenomas are often plurihormonal tumors, which may co-secrete TSH, prolactin, and/or GH.
Exacerbation of disease has been reported with administration of gonadotropin-releasing hormone agonists such as leuprolide.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Follicle-stimulating hormone
- Luteinizing hormone
- Pituitary adenoma
- Ovarian stimulation syndrome
- Testosterone
1 Epidemiology and Clinical Presentation
-
Pituitary adenomas that hypersecrete functional follicle-stimulating hormone (FSH) and/or luteinizing hormone (LH) are extremely rare.
-
Although many nonfunctioning pituitary adenomas demonstrate positive immunoreactivity for FSH and LH, the overwhelming majority of these tumors are clinically silent [1], as discussed previously in chapter 10.
-
In women, functional gonadotroph adenomas may cause ovarian stimulation syndrome with enlarged ovaries, pelvic pain, galactorrhea, and/or menstrual abnormalities [2, 3]. Levels of circulating estradiol are typically elevated.
-
In men, excess levels of serum testosterone with testicular enlargement have been reported.
-
In boys, precocious puberty has been reported.
-
Functioning gonadotroph adenomas are often plurihormonal tumors, which may co-secrete TSH, prolactin, and/or GH.
-
Exacerbation of disease has been reported with administration of gonadotropin-releasing hormone agonists such as leuprolide [4].
2 Diagnosis
2.1 Imaging
-
Imaging characteristics of gonadotroph adenomas are similar to those described for other functioning adenomas.
2.2 Histopathology
-
Adenomas may demonstrate immunoreactivity for FSH, LH, or both, and invariably for the gonadotrophic transcription factor SF-1.
-
Many of these adenomas will also demonstrate immunoreactivity for the alpha-subunit (Fig. 16.1) [5].
-
Electron microscopy may demonstrate different structural features in the adenomas of men versus those of women. Gonadotroph adenomas in men resemble null-cell adenomas, with poorly or moderately developed cytoplasmic organelles. In women, tumors tend to be well differentiated, with distinctive vesicular dilatation of the Golgi complex (“honeycomb Golgi”) [6].
3 Clinical Management
-
As with most functional pituitary adenomas, transsphenoidal surgical resection remains the mainstay of treatment.
-
Dopamine agonist therapy (cabergoline or bromocriptine) has been reported to be an effective medical treatment for a subset of these tumors [7].
-
Successful treatment with a gonadotropin-releasing hormone antagonist also has been reported [8].
-
Resolution of ovarian hyperstimulation, reduction of ovary size, and successful pregnancy have been reported following effective treatment.
-
Gonadotropin-releasing hormone agonists should be avoided in these patients, as they may promote tumor growth [9, 10].
References
Young Jr WF, Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc. 1996;71:649–56.
Valimaki MJ, Tiitinen A, Alfthan H, Paetau A, Poranen A, Sane T, Stenman UH. Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in a 28-year-old woman. J Clin Endocrinol Metab. 1999;84:4204–8.
Cooper O, Geller JL, Melmed S. Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab. 2008;4:234–8.
Castelbaum AJ, Bigdeli H, Post KD, Freedman MF, Snyder PJ. Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma. Fertil Steril. 2002;78:1311–3.
Al-Shraim M, Scheithauer BW, Horvath E, Kovacs K, Smyth H, Coire C, et al. Plurihormonal gonadotroph cell pituitary adenoma: report of a unique case. Clin Neuropathol. 2009;28:182–7.
Horvath E, Kovacs K. Gonadotroph adenomas of the human pituitary: sex-related fine-structural dichotomy. A histologic, immunocytochemical, and electron-microscopic study of 30 tumors. Am J Pathol. 1984;117:429–40.
Knoepfelmacher M, Danilovic DL, Rosa Nasser RH, Mendonca BB. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertil Steril. 2006;86:e715–8.
Garmes HM, Grassiotto OR, Fernandes YB, Queiroz Lde S, Vassalo J, de Oliveira DM, Benetti-Pinto CL. A pituitary adenoma secreting follicle-stimulating hormone with ovarian hyperstimulation: treatment using a gonadotropin-releasing hormone antagonist. Fertil Steril. 2012;97:231–4.
Reznik Y, Chapon F, Lahlou N, Deboucher N, Mahoudeau J. Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer. J Endocrinol Invest. 1997;20:566–8.
Macchia E, Simoncini T, Raffaelli V, Lombardi M, Iannelli A, Martino E. A functioning FSH-secreting pituitary macroadenoma causing an ovarian hyperstimulation syndrome with multiple cysts resected and relapsed after leuprolide in a reproductive-aged woman. Gynecol Endocrinol. 2012;28:56–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Zada, G., Lopes, M.B.S., Mukundan, S., Laws, E. (2016). Gonadotroph Adenomas. In: Zada, G., Lopes, M., Mukundan Jr., S., Laws Jr., E. (eds) Atlas of Sellar and Parasellar Lesions. Springer, Cham. https://doi.org/10.1007/978-3-319-22855-6_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-22855-6_16
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22854-9
Online ISBN: 978-3-319-22855-6
eBook Packages: MedicineMedicine (R0)